Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Eur J Pharmacol ; 874: 172986, 2020 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-32032601

RESUMO

Diarrhea is a condition in which the individual has about three or more daily bowel movements, followed by changes in stool consistency. It is currently considered as one of the worst public health problems due to the number of cases and deaths involved and difficulty of treatment. Thus, the use of natural products is an alternative for new treatments. Among these possibilities is Farnesol (C15H26O), a sesquiterpene found in different herbal species that has known biological activities. The objective of this study was to evaluate the antidiarrheal activity of Farnesol (FOH). Initially, FOH activity was evaluated in models of diarrhea and enteropooling induced by castor oil and PGE2. To evaluate motility, the opioid and cholinergic pathways were studied. In addition, the effect of FOH was investigated in the secretion model in intestinal loops treated with cholera toxin. FOH was evaluated for the ability to absorb fluids in intestinal loops and interact with GM1 receptors using the ELISA method and molecular docking. The dose of 50 mg/kg of FOH showed the best results in all antidiarrheal activity tests with castor oil and PGE2, being considered as the standard dose, reducing motility by anticholinergic mechanisms. There was a reduction in fluid secretion when FOH interacted directly with GM1 receptors; cholera toxin and molecular docking showed strong interaction between farnesol and these targets. In view of the results presented, the antidiarrheal activity occurs through anticholinergic, anti-inflammatory and anti-secretory action, making farnesol a potential candidate for the development of a new drug to treat diarrheal diseases.


Assuntos
Antidiarreicos/farmacologia , Antidiarreicos/uso terapêutico , Diarreia/tratamento farmacológico , Diarreia/metabolismo , Farneseno Álcool/farmacologia , Farneseno Álcool/uso terapêutico , Animais , Óleo de Rícino , Cloretos/metabolismo , Toxina da Cólera , Diarreia/induzido quimicamente , Dinoprostona , Feminino , Motilidade Gastrointestinal/efeitos dos fármacos , Absorção Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Secreções Intestinais/metabolismo , Masculino , Camundongos , Simulação de Acoplamento Molecular , Naloxona/farmacologia , Antagonistas de Entorpecentes/farmacologia , Receptores de Superfície Celular/metabolismo
2.
Biomed Pharmacother ; 110: 631-640, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30540974

RESUMO

Diarrhea is one of the leading causes of infant death in the world accounting for high child mortality rate. It is also present in different pathophysiologies related to several etiological agents. The aim of this study is to investigate the antidiarrheal effect of α -Terpineol (α-TPN) in different diarrhea models in rodents. The antidiarrheal effect of α-TPN in the treatment of acute diarrhea and enteropooling induced by castor oil or PGE2 in Swiss mice pretreated orally with saline (NaCl 0.9%), Loperamide (5 mg/kg) and α-TPN (6.25, 12.5, 25 and 50 mg/kg) was analyzed. Additionally, parameters of severity, total weight of faeces and post-treatment for 4 h were evaluated. Modulation of the opioid and cholinergic pathways was performed and intestinal transit model using activated charcoal as marker was also used. The effect of α-TPN on secretory diarrhea was investigated using the model of fluid secretion in intestinal loops isolated from cholera toxin-treated mice. α-TPN showed antidiarrheal effect (*p < 0.05), reducing the total stool amount (*55%, *48%, *44%, *24%) and diarrheal (*47%, *66%; *56%, 10%) respectively for the doses tested. All doses investigated in the enteropooling test presented significant changes (*46%, *78%, *66%, *41% respectively) in relation to the control. α-TPN through the muscarinic pathway reduced the gastrointestinal transit (*31%), besides inhibiting PGE2-induced diarrhea (*39%). α-TPN also reduced fluid formation and loss of Cl- ions, by interacting directly with GM1 receptors and cholera toxin, thus increasing the uptake of intestinal fluids. The results suggest an anti-diarrheal activity of α-TPN due to its anticholinergic action, ability to block PGE2 and GM1 receptors and interaction with cholera toxin in secretory diarrhea, making it a promising candidate drug for the treatment of diarrheal diseases.


Assuntos
Antidiarreicos/uso terapêutico , Cicloexenos/uso terapêutico , Diarreia/tratamento farmacológico , Motilidade Gastrointestinal/efeitos dos fármacos , Monoterpenos/uso terapêutico , Animais , Antidiarreicos/farmacologia , Óleo de Rícino/toxicidade , Monoterpenos Cicloexânicos , Cicloexenos/farmacologia , Diarreia/induzido quimicamente , Diarreia/fisiopatologia , Relação Dose-Resposta a Droga , Feminino , Motilidade Gastrointestinal/fisiologia , Masculino , Camundongos , Monoterpenos/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA